Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial.

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Thrombosis Research

Background:

• Post-cesarean delivery thromboprophylaxis is crucial for preventing venous thromboembolism (VTE).
• Enoxaparin is commonly used, but optimal dosing strategies (fixed vs. weight-based) require evaluation.
• Achieving therapeutic anti-Xa levels is essential for effective prophylaxis.

Purpose of the Study:

• To compare the efficacy of fixed-dose versus weight-based enoxaparin in achieving prophylactic anti-Xa levels after cesarean delivery.
• To assess the rates of subprophylactic and supraprophylactic anti-Xa levels with both dosing regimens.
• To evaluate the incidence of VTE and wound complications in the postpartum period.

Main Methods:

• Randomized trial comparing fixed (40 mg daily or every 12 hours based on BMI) and weight-based (0.5 mg/kg every 12 hours) enoxaparin dosing.
• Enoxaparin initiated during hospitalization and continued for 14 days postpartum.
• Primary outcome: prophylactic peak anti-Xa level (0.2-0.6 IU/mL) at steady state; secondary outcomes included VTE and wound complications.

Main Results:

• Weight-based dosing achieved prophylactic anti-Xa levels more frequently than fixed dosing (66% vs. 44% primary analysis).
• Subprophylactic levels were more common with fixed dosing.
• No significant difference in VTE events; wound complications were slightly higher with weight-based dosing (7% vs. 1%).

Conclusions:

• Weight-based enoxaparin dosing is superior to fixed dosing for achieving prophylactic anti-Xa levels in patients after cesarean delivery.
• This dosing strategy may offer improved thromboprophylaxis.
• Further research may be warranted to fully assess the risk-benefit profile, particularly regarding wound complications.